FrancophonIA/ELRC3.0 huggingface dataset:
English: The most common side effects with Relvar Ellipta (which may affect more than 1 in 10 people) are headache and nasopharyngitis (inflammation of the nose and throat).
Estonian: Relvar Ellipta kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on peavalu ja nasofarüngiit (nina- ja kurgupõletik).
English: In COPD, it is used in adults who have flare-ups of the disease despite regular bronchodilator treatment (treatment to widen the airways).
Estonian: Kroonilise obstruktiivse kopsuhaiguse korral kasutatakse seda täiskasvanutel, kellel esineb hoolimata regulaarsest ravist bronhodilaatoriga (hingamisteid laiendav ravi) haiguse ägenemisi.
English: More serious side effects include pneumonia and fractures (seen in up to 1 in 10 people), which were reported more often in patients with COPD than those with asthma.
Estonian: Raskemad kõrvalnähud on muu hulgas kopsupõletik ja luumurrud (esinevad kuni 1 patsiendil 10st), millest teatati kroonilise obstruktiivse kopsuhaigusega patsientidel sagedamini kui astmaga patsientidel.
English: In two further studies, Relvar Ellipta reduced the number of flare-ups by between 13 and 34% more than vilanterol alone.
Estonian: Kahes ülejäänud uuringus vähenes Relvar Ellipta kasutamisel ägenemiste arv 13-34% rohkem kui ainult vilanterooli kasutamise korral.
English: Relvar Ellipta 184/22 also improved FEV1 by 193 ml more than fluticasone furoate and 210 ml more than another inhaler containing fluticasone propionate.
Estonian: Relvar Ellipta 184/22 korral suurenes FEV1 väärtus 193 ml võrra rohkem kui flutikasoonfuroaadi korral ja 210 ml võrra rohkem kui flutikasoonpropionaati sisaldava teise inhalaatori korral.
English: A fourth study in 1,522 patients showed that Relvar Ellipta was as effective as another medicine containing a corticosteroid (fluticasone propionate) and a long-acting beta-2 agonist (salmeterol).
Estonian: Neljandas uuringus, milles osales 1522 patsienti, tõendati, et Relvar Ellipta oli sama efektiivne kui võrdlusravimina kasutatud teine kortikostreoidi (flutikasoonpropionaati) ja pikatoimelist beeta-2agonisti (salmetarooli) sisaldav ravim.
English: Relvar Ellipta contains the active substances fluticasone furoate and vilanterol.
Estonian: Relvar Ellipta sisaldab toimeainetena flutikasoonfuroaati ja vilanterooli.
English: This reduces inflammation in the airways and improves the patient's breathing.
Estonian: See vähendab hingamisteedes põletikku ja muudab hingamise patsiendi jaoks kergemaks.
English: In a third study, fewer patients taking Relvar Ellipta 92/22 had at least one severe flare-up after a year of treatment than those taking fluticasone furoate alone (13% versus 16%).
Estonian: Kolmas uuring näitas, et Relvar Elliptat 92/22 võtnud patsientide seas oli neid, kellel oli aasta jooksul pärast ravi alustamist esinenud vähemalt üks raske ägenemine, vähem kui nende seas, kes võtsid ainult flutikasoonfuroaati (vastavalt 13% ja 16%).
English: These patients were already well controlled with the comparator medicine and Relvar Ellipta treatment was able to maintain their FEV1.
Estonian: Nende patsientide haigus allus juba piisavalt ravile võrdlusravimiga ja ravi Relvar Elliptaga hoidis FEV1 väärtuse samal tasemel.
English: For the full list of side effects of Relvar Ellipta, see the package leaflet.
Estonian: Relvar Ellipta kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: What are the risks associated with Relvar Ellipta?
Estonian: Mis riskid Relvar Elliptaga kaasnevad?
English: It attaches to beta-2 receptors in the airways and causes the muscles of the airways to relax and widen, allowing the patient to breathe more easily.
Estonian: See kinnitub hingamisteedes β2-retseptoritele, lõõgastades nii hingamisteede lihased ja hoides hingamisteed avatuna, nii et patsiendil on kergem hingata.
English: In two of the studies, Relvar Ellipta 92/22 increased the volume of air a patient could breathe out in one second (FEV1) by 36 ml more than fluticasone furoate alone and 172 ml more than placebo (a dummy treatment).
Estonian: Neist kahes uuringus suurendas Relvar Ellipta 92/22 õhukogust, mida patsient suudab välja hingata ühes sekundis (FEV1), 36 ml võrra rohkem kui ainult flutikasoonfuroaat ja 172 ml rohkem kui platseebo (näiv ravim).
English: The first study showed that Relvar Ellipta 92/22 improved average FEV1 by 115 ml more than placebo, and a second study showed that Relvar Ellipta 184/22 improved average FEV1 by 131 ml more than placebo.
Estonian: Esimeses uuringus suurenes Relvar Ellipta 92/22 kasutamisel FEV1 väärtus keskmiselt 115 ml võrra rohkem kui platseebo korral ja teises uuringus suurenes Relvar Ellipta 184/22 kasutamisel FEV1väärtus keskmiselt 131 ml võrra rohkem kui platseebo korral.
English: Relvar Ellipta is an inhaler for treating asthma and chronic obstructive pulmonary disease (COPD).
Estonian: Relvar Ellipta on inhalaator, mida kasutatakse astma ja kroonilise obstruktiivse kopsuhaiguse raviks.
English: How is Relvar Ellipta used?
Estonian: Kuidas Relvar Elliptat kasutatakse?
English: • whose symptoms are not controlled with an inhaled corticosteroid and an inhaled short-acting
Estonian: • kelle sümptomid ei allu piisavalt ravile inhaleeritava kortikosteroidi ja inhaleeritava lühitoimelise beeta-2-agonistiga või
English: Four studies in over 5,500 patients showed that Relvar Ellipta improves breathing and reduces flareups of symptoms in patients with COPD.
Estonian: Neljast uuringust, milles osales üle 5500 patsiendi, nähtus, et Relvar Ellipta kergendab kroonilise obstruktiivse kopsuhaigusega patsientide hingamist ja vähendab sümptomite ägenemisi.
English: What benefits of Relvar Ellipta have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Relvar Ellipta kasulikkus?
English: An overview of Relvar Ellipta and why it is authorised in the EU
Estonian: Ülevaade ravimist Relvar Ellipta ja ELis müügiloa väljastamise põhjendus
English: Regarding its safety, the most frequent side effects reported with Relvar Ellipta were similar to those seen with other COPD and asthma treatments; an increased incidence of pneumonia was observed in patients with COPD.
Estonian: Ravimi ohutusprofiili osas sarnanes enamik Relvar Elliptaga teatatud kõrvalnähte muude kroonilise obstruktiivse kopsuhaiguse ja astmaravimite kõrvalnähtudega; kroonilise obstruktiivse kopsuhaigusega patsientidel esines sagedamini kopsupõletikku.
English: Three studies in over 3,200 patients showed that Relvar Ellipta improves breathing and reduces flareups in patients with asthma.
Estonian: Kolmest põhiuuringust, milles osales kokku üle 3200 patsiendi, nähtus, et Relvar Ellipta kergendab astmaga patsientidel hingamist ja vähendab haiguse ägenemisi.
English: • whose symptoms are adequately controlled with both inhaled corticosteroids and a long-acting
Estonian: • kelle sümptomid alluvad piisavalt ravile inhaleeritavate kortikosteroidide ja pikatoimelise beeta-2
English: The doctor will decide which inhaler the patient should use.
Estonian: Sobiva inhalaatori määrab patsiendile arst.
English: How does Relvar Ellipta work?
Estonian: Kuidas Relvar Ellipta toimib?
English: Relvar Ellipta contains two active substances that work in different ways to improve breathing in patients with asthma and COPD.
Estonian: Relvar Ellipta sisaldab kaht toimeainet, mis kumbki kergendab astma või kroonilise obstruktiivse kopsuhaigusega patsientide hingamist erineval viisil.
English: Relvar Ellipta can only be obtained with a prescription.
Estonian: Relvar Ellipta on retseptiravim.
English: Relvar Ellipta improves breathing and reduces flare ups of symptoms in patients with asthma and COPD.
Estonian: Relvar Ellipta kergendab astma ja kroonilise obstruktiivse kopsuhaigusega patsientidel hingamist ja vähendab sümptomite ägenemisi.
English: Why is Relvar Ellipta authorised in the EU?
Estonian: ELis Relvar Elliptale väljastatud müügiloa põhjendus
English: What is VeraSeal?
Estonian: Mis on VeraSeal?
English: The Committee was concerned that the main study had not been carried out in accordance with the guidelines for Good Clinical Practice (GCP).
Estonian: Komitee oli mures, et põhiuuringut ei viidud läbi kooskõlas hea kliinilise tava suunistega.
English: The applicant presented data from one main study involving 167 patients who underwent vascular surgery.
Estonian: Taotleja esitas ühe põhiuuringu andmed 167 patsiendi kohta, kellele tehti veresoonte operatsioon.
English: EMA/679015/2015
Estonian: oktoober 2015 EMA/749925/2015 EMEA/H/C/003914
English: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom23 October 2015 EMA/679015/2015 EMEA/H/C/003914
Estonian: 30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom23.
English: Findings from a GCP inspection of the study sites raised serious questions about the data from the main study submitted in support of the application.
Estonian: Uuringu hea kliinilise tava kohase kohapealse kontrollkäigu tähelepanekud tekitasid tõsiseid küsimusi seoses põhiuuringu andmetega, mis esitati taotluse toetamiseks.
English: VeraSeal is a medicine that contains the active substances human fibrinogen and human thrombin.
Estonian: VeraSeal on ravim, mis sisaldab toimeainetena inimfibrinogeeni ja inimtrombiini.
English: It was to be available as two separate solutions that are mixed together to prepare a sealant that is applied to the surface of blood vessels.
Estonian: Seda kavatseti turustada kahe eraldi lahusena, mis segatakse kokku veresoonte pinnale määritava koeliimi valmistamiseks.
English: The active substances in VeraSeal, human fibrinogen and human thrombin, are natural proteins in the blood and are obtained from blood donors.
Estonian: VeraSeali toimeained inimfibrinogeen ja inimtrombiin on looduslikud verevalgud, mida saadakse veredoonoritelt.
English: The main measure of effectiveness was the ability to stop bleeding during a 10-minute observation period, after applying the method to stop the bleeding.
Estonian: Efektiivsuse põhinäitaja oli suutlikkus peatada verejooks 10-minutilise jälgimisperioodi jooksul pärast verejooksu peatamise meetodi kasutamist.
English: There are no consequences for patients in the three ongoing clinical trials.
Estonian: Kolmes käimasolevas kliinilises uuringus osalevatele patsientidele tagasivõtmine mõju ei avalda.
English: The company informed the CHMP that there are currently no ongoing compassionate use programmes for VeraSeal.
Estonian: Ettevõte teatas inimravimite komiteele, et VeraSealiga ei viida praegu läbi eriloaga kasutamise programme.
English: The fibrin then aggregates (sticks together) and forms fibrin clots on the surface of blood vessels.
Estonian: Seejärel fibriin agregeerub (kleepub kokku) ja moodustab veresoonte pinnal fibriinhüübe.
English: When applied to a moist surface, the thrombin is activated and cuts fibrinogen up into smaller units called fibrin.
Estonian: Trombiini kandmisel niiskele pinnale see aktiveerub ja lagundab fibrinogeeni väiksemateks osadeks ehk fibriiniks.
English: In its letter notifying the Agency of the withdrawal of the applications, the company stated that the withdrawal was due to not being able to gather the additional data required by the CHMP, including data from three ongoing clinical studies with the product, within the available timeframe.
Estonian: Kirjas, milles ettevõte teatab Euroopa Ravimiametile oma taotluste tagasivõtmisest, väitis ettevõte, et tagasivõtmise põhjus on asjaolu, et ta ei suutnud tähtajaks koguda inimravimite komitee nõutud lisaandmeid, sh ravimi kolme käimasoleva kliinilise uuringu andmed.
English: Therefore, at the time of the withdrawal, the CHMP was of the opinion that the company had not provided enough data to support the application for VeraSeal.
Estonian: Seetõttu oli inimravimite komitee müügiloa taotluse tagasivõtmise ajal arvamusel, et ettevõte ei ole esitanud piisavalt andmeid ravimi VeraSeal taotluse toetuseks.
English: How is VeraSeal expected to work?
Estonian: Milline on VeraSeali eeldatav toime?
English: This helps prevent bleeding and seals the blood vessels.
Estonian: See aitab veritsust ära hoida ja suleb veresooned.
English: Based on the review of the data and the company's response to the CHMP lists of questions, at the time of the withdrawal the CHMP had concerns and was of the provisional opinion that VeraSeal could not have been approved to help stop bleeding during vascular surgery.
Estonian: Tuginedes esitatud andmete analüüsile ja ettevõtte vastustele inimravimite komitee esitatud küsimustele, nägi komitee taotluse tagasivõtmise ajal põhjust ettevaatlikkuseks ja oli esialgsel seisukohal, et ravimi VeraSeal kasutamist verejooksu peatamiseks veresoonte operatsiooni ajal ei ole võimalik heaks kiita.
English: On 29 September 2015, Instituto Grifols S.A. officially notified the Committee for Medicinal Products for Human Use (CHMP) that it wishes to withdraw its application for marketing authorisation of VeraSeal, which was intended to help stop bleeding during vascular (blood vessel) surgery when standard surgical methods for controlling bleeding are insufficient.
Estonian: Instituto Grifols S.A. teatas 29. septembril 2015 ametlikult inimravimite komiteele oma soovist võtta tagasi ravimi VeraSeal müügiloa taotlus.
English: VeraSeal was expected to be used to help stop bleeding during vascular surgery when standard surgical methods for controlling bleeding are insufficient.
Estonian: VeraSeali kavatseti kasutada veresoonte operatsiooni ajal verejooksu peatamiseks, kui verejooksu peatamise standardsed kirurgilised meetodid on ebapiisavad.
English: What was VeraSeal expected to be used for?
Estonian: Milleks kavatseti VeraSeali kasutada?
English: In this study, bleeding during surgery was managed either by applying VeraSeal or by
Estonian: Selles uuringus ohjati operatsiooni ajal verejooksu kas VeraSeali pealemäärimise või veresoonte komprimeerimise (operatsiooni ajal verejooksu peatamise standardmeetod) abil.
English: This summary was last updated in 05-2008.
Estonian: Kokkuvõtte viimane uuendus: 05-2008.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Pelzont to Merck Sharp & Dohme Ltd. on 3 July 2008.
Estonian: Euroopa Komisjon andis Pelzonti müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Merck Sharp & Dohme Ltd 3. juulil 2008.
English: The Committee recommended that Pelzont be given marketing authorisation.
Estonian: Komitee soovitas anda Pelzontile müügiloa.
English: The tablets must be swallowed whole, and should not be split, broken, crushed or chewed.
Estonian: Tabletid tuleb alla neelata tervelt ja neid ei tohi poolitada, katki murda, purustada ega närida.
English: Primary means that the hypercholesterolaemia does not have any identifiable cause.
Estonian: Primaarne tähendab, et hüperkolesteroleemial ei ole selgelt tuvastatavat põhjust.
English: It is taken by mouth, with food, in the evening or before going to bed.
Estonian: Tablette manustatakse suu kaudu koos toiduga õhtul või enne magamaminekut.
English: ‘Modified-release' means that the two active substances are released at different rates from the tablet over a few hours.
Estonian: „Modifitseeritult vabastav” tähendab, et toimeained vabanevad tabletist mõne tunni jooksul eri kiirusega.
English: Laropiprant blocks the receptors to which PGD2 normally attaches.
Estonian: Laropiprant blokeerib retseptoreid, millega PGD2 tavaliselt seondub.
English: The starting dose of Pelzont is one tablet once a day for four weeks, after which the dose is increased to two tablets once a day.
Estonian: Pelzonti algannus on üks tablett üks kord ööpäevas nelja nädala jooksul; seejärel suurendatakse annust kahe tabletini üks kord ööpäevas.
English: Pelzont is not recommended for use in children under 18 years of age because of a lack of information on its safety and effectiveness in this group.
Estonian: Alla 18-aastastel lastel ja noorukitel ei soovitata Pelzonti kasutada, sest andmed ravimi kasutamise ohutuse ja efektiivsuse kohta selles patsiendirühmas puuduvad.
English: The most common side effect with Pelzont (seen in more than 1 patient in 10) is flushing.
Estonian: Pelzonti kõige sagedam kõrvalnäht (esinenud enam kui ühel patsiendil kümnest) on nahapunetus.
English: When the receptors are blocked, PGD2 cannot dilate the vessels in the skin, reducing the frequency and intensity of flushing.
Estonian: Kui retseptorid on blokeeritud, ei saa PGD2 nahaveresooni laiendada, mis vähendab nahapunetuse esinemissagedust ja tugevust.
English: Pelzont is normally given together with a statin (the standard medicine used to reduce cholesterol) when the effectiveness of a statin taken alone is inadequate.
Estonian: Pelzonti manustatakse tavaliselt koos statiiniga (kolesteroolisisalduse vähendamise tavaline ravim), kui ravi üksnes statiiniga ei ole efektiivne.
English: They included a total of 2,349 patients who were taking either Pelzont or nicotinic acid.
Estonian: Uuringutes osales kokku 2349 patsienti, kes võtsid kas Pelzonti või nikotiinhapet.
English: It was first used as a medicine to modify blood fat levels in the mid-1950s, but its use has been limited because of its side effects, particularly flushing (reddening of the skin).
Estonian: Esimest korda kasutati nikotiinhapet vere rasvasisalduse muutmiseks 1950. aastate keskel, kuid aine kasutamist piiravad kõrvalnähud, eelkõige nahapunetus.
English: It should also not be used in patients who have problems with their liver, an active stomach ulcer or bleeding from an artery.
Estonian: Ravimit ei tohi kasutada ka patsiendid, kellel on maksaprobleeme, aktiivne maohaavand või arteriaalne verejooks.
English: Pelzont is a medicine containing two active substances: nicotinic acid (also known as niacin or vitamin B3) and laropiprant.
Estonian: Pelzont on ravim, mis sisaldab kahte toimeainet: nikotiinhapet (teiste nimetustega niatsiin ja vitamiin B3) ning laropipranti.
English: What is Pelzont?
Estonian: Mis on Pelzont?
English: It should be used with caution in patients who have problems with their kidneys and should not be used in patients with liver problems.
Estonian: Neeruprobleemidega patsiendid peavad ravimit kasutama ettevaatlikult ja seda ei tohi võtta maksaprobleemidega patsiendid.
English: The main measure of effectiveness was the change in the blood levels of LDL cholesterol after 12 weeks.
Estonian: Efektiivsust hinnati põhiliselt vere LDL-kolesterooli sisalduse muutuse järgi pärast 12-nädalast ravi.
English: Pelzont was effective in reducing the blood levels of LDL cholesterol.
Estonian: Pelzont vähendas efektiivselt LDL-kolesterooli sisaldust veres.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) PELZONT EPAR summary for the public
Estonian: EUROOPA AVALIK HINDAMISARUANNE PELZONT Kokkuvõte üldsusele
English: It is available as modified-release tablets.
Estonian: Ravimit turustatakse toimeainet modifitseeritult vabastavate tablettidena.
English: Two studies looked at the effectiveness of Pelzont in modifying blood fat levels.
Estonian: Kahes uuringus uuriti Pelzonti efektiivsust vere rasvasisalduse mõjutamisel.
English: The third and fourth studies looked at the effectiveness of laropiprant in reducing the flushing caused by nicotinic acid.
Estonian: Kolmandas ja neljandas uuringus vaadeldi laropiprandi efektiivsust nikotiinhappe põhjustatud nahapunetuse vähendamisel.
English: Nicotinic acid is a naturally occurring substance that is used in low doses as a vitamin.
Estonian: Nikotiinhape on looduslik aine, mida kasutatakse väikestes annustes vitamiinina.
English: What is the risk associated with Pelzont?
Estonian: Mis riskid Pelzontiga kaasnevad?
English: Pelzont should not be used in people who may be hypersensitive (allergic) to nicotinic acid, laropiprant or any of the other ingredients.
Estonian: Pelzonti ei tohi kasutada patsiendid, kes võivad olla nikotiinhappe, laropiprandi või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The second study showed that the LDL cholesterol levels were further reduced when Pelzont was taken with simvastatin (48% reduction), compared with Pelzont alone (17% reduction) or simvastatin alone (37% reduction).
Estonian: Teine uuring näitas, et LDL-kolesterooli sisaldus vähenes veelgi, kui Pelzonti manustati koos simvastatiiniga (48% võrra), samas kui LDL-kolesterooli sisaldus vähenes Pelzonti kui ainuravimi korral 17% võrra ja simvastatiini kui ainuravimi korral 37% võrra.
English: This study also looked at the symptoms of flushing using a specially designed questionnaire.
Estonian: Selles uuringus uuriti spetsiaalsete küsimustike abil ka nahapunetuse sümptomeid.
English: Why has Pelzont been approved?
Estonian: Miks Pelzont heaks kiideti?
English: When the patient takes the tablet, laropiprant is released first into the bloodstream and blocks the PGD2 receptors.
Estonian: Allaneelatud tabletist vabaneb kõigepealt laropiprant, mis jõuab esimesena ka vereringesse ja blokeerib PGD2 retseptorid.
English: For the full list of all side effects reported with Pelzont, see the Package Leaflet.
Estonian: Pelzonti kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: Pelzont was studied in four main studies in patients with hypercholesterolaemia or mixed dyslipidaemia.
Estonian: Pelzonti neljas põhiuuringus uuriti hüperkolesteroleemia või segatüüpi düslipideemiga patsiente.
English: Patients with combined mixed dyslipidaemia have high blood levels of ‘bad' LDL cholesterol and triglycerides (a type of fat), and low levels of ‘good' HDL cholesterol.
Estonian: Kombineeritud segatüüpi düslipideemiaga patsientidel on veres suur nn halva LDL-kolesterooli ja triglütseriidide (teatud tüüpi rasvad) sisaldus ning väike nn hea HDLkolesterooli sisaldus.
English: Adding laropiprant to nicotinic acid reduced the symptoms of flushing caused by nicotinic acid.
Estonian: Laropiprandi lisamine nikotiinhappele vähendas nikotiinhappest tingitud nahapunetust.
English: The second study compared the combination of Pelzont and simvastatin (a statin) with Pelzont alone or simvastatin alone in 1,398 patients.
Estonian: Teises uuringus võrreldi Pelzonti ja simvastatiini (statiin) kombinatsiooni toimet ainult Pelzonti või simvastatiini toimega kokku 1398 patsiendil.
English: In higher doses, it reduces the levels of fat in the blood via a mechanism that is not fully understood.
Estonian: Suurtes annustes vähendab aine vere rasvasisaldust, kuid selle toimemehhanism ei ole seni veel täiesti teada.
English: The nicotinic acid is released more slowly from the other layer and has its effect as a fatmodifying agent.
Estonian: Nikotiinhape vabaneb teisest kihist aeglasemalt ja mõjutab vere rasvasisaldust.
English: In the first study, LDL cholesterol levels were reduced by 19% in patients taking Pelzont, compared with 1% in those taking placebo.
Estonian: Esimeses uuringus vähenes LDLkolesterooli sisaldus Pelzonti saanud patsientidel 19% võrra ja platseebot saanud patsientidel 1% võrra.
English: The two active substances in Pelzont, nicotinic acid and laropiprant, have different modes of action.
Estonian: Pelzonti kahel toimeainel (nikotiinhape ja laropiprant) on eri toimemehhanismid.
English: Pelzont is used on its own only in patients who cannot take statins.
Estonian: Ilma statiinita kasutatakse Pelzonti ainult juhul, kui patsient ei saa statiine võtta.
English: Flushing due to nicotinic acid is thought to occur because of the release of a substance called ‘prostaglandin D2' (PGD2) from cells in the skin, which dilates (widens) the blood vessels in the skin.
Estonian: Arvatakse, et nikotiinhappe põhjustatud nahapunetuse põhjus on, et naharakkudest vabaneb aine prostaglandiin D2 (PGD2), mis laiendab nahaveresooni.
English: In Pelzont tablets, laropiprant is in one of the layers, and the other layer contains nicotinic acid.
Estonian: Pelzonti tablettides sisaldub laropiprant ühes kihis ja nikotiinhape teises.
English: The full EPAR for Pelzont can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Pelzonti kohta leiate siit.
English: In the fourth study, flushing was seen on fewer days in patients taking Pelzont than in those taking nicotinic acid alone.
Estonian: Neljandas uuringus täheldati nahapunetust lühema perioodi vältel nende patsientide hulgas, kes said Pelzonti, võrreldes patsientidega, kes võtsid ainult nikotiinhapet.